Price
Financials
Standalone, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 16.61 | 17.43 | 15.60 | 17.05 | 17.70 | 18.37 | 14.07 | 16.70 | 17.62 | 18.76 | 16.85 | 16.39 |
| Expenses | 15.79 | 16.92 | 15.00 | 16.64 | 16.78 | 17.37 | 13.62 | 16.17 | 16.76 | 17.72 | 16.28 | 15.86 |
| Operating Profit | 0.82 | 0.51 | 0.60 | 0.41 | 0.92 | 1.00 | 0.45 | 0.53 | 0.86 | 1.04 | 0.57 | 0.53 |
| OPM % | 4.94% | 2.93% | 3.85% | 2.40% | 5.20% | 5.44% | 3.20% | 3.17% | 4.88% | 5.54% | 3.38% | 3.23% |
| Other Income | 0.09 | 0.03 | 0.31 | 0.04 | 0.03 | 0.02 | 0.07 | 0.02 | 0.05 | 0.01 | 0.37 | 0.02 |
| Interest | 0.01 | 0.02 | 0.01 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
| Depreciation | 0.13 | 0.14 | 0.19 | 0.16 | 0.17 | 0.19 | 0.15 | 0.18 | 0.17 | 0.17 | 0.16 | 0.16 |
| Profit before tax | 0.77 | 0.38 | 0.71 | 0.27 | 0.75 | 0.80 | 0.34 | 0.34 | 0.71 | 0.85 | 0.75 | 0.36 |
| Tax % | 27.27% | 44.74% | 16.90% | 40.74% | 32.00% | 30.00% | 2.94% | 35.29% | 26.76% | -14.12% | 93.33% | 36.11% |
| Net Profit | 0.55 | 0.21 | 0.59 | 0.17 | 0.50 | 0.56 | 0.33 | 0.22 | 0.52 | 0.98 | 0.04 | 0.23 |
| EPS in Rs | 0.57 | 0.22 | 0.61 | 0.18 | 0.52 | 0.58 | 0.34 | 0.23 | 0.54 | 1.01 | 0.04 | 0.24 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 38.86 | 42.82 | 49.02 | 49.42 | 48.37 | 58.76 | 65.50 | 65.35 | 67.28 | 67.19 | 69.93 | 69.62 |
| Expenses | 35.97 | 40.97 | 46.55 | 47.33 | 46.92 | 56.60 | 62.62 | 62.86 | 64.98 | 64.43 | 66.93 | 66.62 |
| Operating Profit | 2.89 | 1.85 | 2.47 | 2.09 | 1.45 | 2.16 | 2.88 | 2.49 | 2.30 | 2.76 | 3.00 | 3.00 |
| OPM % | 7.44% | 4.32% | 5.04% | 4.23% | 3.00% | 3.68% | 4.40% | 3.81% | 3.42% | 4.11% | 4.29% | 4.31% |
| Other Income | 0.12 | 0.56 | 0.12 | 0.57 | 0.45 | 0.19 | 0.08 | 0.33 | 0.42 | 0.17 | 0.44 | 0.45 |
| Interest | 1.64 | 1.49 | 1.23 | 1.01 | 0.43 | 0.11 | 0.11 | 0.08 | 0.06 | 0.10 | 0.11 | 0.12 |
| Depreciation | 0.69 | 0.87 | 0.60 | 0.64 | 0.55 | 0.56 | 0.53 | 0.52 | 0.58 | 0.67 | 0.68 | 0.66 |
| Profit before tax | 0.68 | 0.05 | 0.76 | 1.01 | 0.92 | 1.68 | 2.32 | 2.22 | 2.08 | 2.16 | 2.65 | 2.67 |
| Tax % | 22.06% | 1,000.00% | 26.32% | 34.65% | 21.74% | 35.12% | 31.47% | 31.08% | 29.33% | 28.24% | 33.58% | |
| Net Profit | 0.54 | -0.44 | 0.56 | 0.67 | 0.72 | 1.09 | 1.59 | 1.52 | 1.46 | 1.55 | 1.77 | 1.77 |
| EPS in Rs | 0.76 | -0.62 | 0.79 | 0.95 | 1.02 | 1.38 | 1.80 | 1.57 | 1.51 | 1.60 | 1.83 | 1.83 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 36.33% | 41.56% | 0.00% | 52.93% | 49.86% | 0.00% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | 6% | 4% | 2% | 4% | ||
| Compounded Profit Growth | 12% | 10% | 5% | 10% | ||
| Stock Price CAGR | 2% | -6% | -21% | -22% | ||
| Return on Equity | 3% | 4% | 4% | 4% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7.08 | 7.08 | 7.08 | 7.08 | 7.08 | 7.08 | 7.92 | 8.81 | 9.66 | 9.66 | 9.66 | 9.66 |
| Reserves | 11.06 | 11.60 | 20.33 | 21.00 | 21.71 | 22.16 | 25.57 | 27.66 | 29.58 | 30.93 | 32.36 | 34.01 |
| Borrowings | 12.47 | 11.39 | 10.56 | 9.42 | 6.17 | 1.25 | 0.02 | 0.00 | 0.00 | 0.00 | 0.06 | 0.11 |
| Other Liabilities | 10.91 | 11.33 | 8.46 | 7.03 | 8.67 | 10.92 | 13.45 | 12.81 | 14.92 | 11.83 | 13.64 | 12.09 |
| Total Liabilities | 41.52 | 41.40 | 46.43 | 44.53 | 43.63 | 41.41 | 46.96 | 49.28 | 54.16 | 52.42 | 55.72 | 55.87 |
| Fixed Assets | 8.36 | 7.81 | 17.49 | 17.57 | 17.04 | 16.60 | 16.17 | 16.00 | 16.62 | 17.88 | 18.15 | 18.12 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.48 | 0.42 | 0.00 | 0.00 | 0.06 |
| Investments | 0.70 | 0.73 | 0.99 | 1.12 | 1.13 | 0.82 | 0.24 | 9.11 | 9.66 | 10.43 | 11.22 | 12.30 |
| Other Assets | 32.46 | 32.86 | 27.95 | 25.84 | 25.46 | 23.99 | 30.55 | 23.69 | 27.46 | 24.11 | 26.35 | 25.39 |
| Total Assets | 41.52 | 41.40 | 46.43 | 44.53 | 43.63 | 41.41 | 46.96 | 49.28 | 54.16 | 52.42 | 55.72 | 55.87 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 4.75 | -1.43 | 4.91 | 1.23 | 3.74 | 6.20 | 7.59 | 0.95 | 0.22 | 0.76 | 0.95 | 6.12 |
| Cash from Investing Activity | -0.18 | 0.05 | -0.59 | -0.62 | -0.10 | -0.37 | -5.58 | -5.47 | 0.53 | -1.31 | -0.18 | -0.57 |
| Cash from Financing Activity | -1.90 | -2.06 | -2.33 | -1.89 | -4.26 | -5.36 | 1.30 | 0.93 | 0.58 | -0.72 | -0.46 | -0.94 |
| Net Cash Flow | 2.67 | -3.44 | 1.99 | -1.28 | -0.62 | 0.48 | 3.31 | -3.59 | 1.33 | -1.27 | 0.31 | 4.60 |
| Free Cash Flow | 4.43 | -1.58 | 4.30 | 0.60 | 3.63 | 6.09 | 7.46 | 0.11 | -0.85 | -0.67 | 0.01 | 5.40 |
| CFO/OP | 201% | -42% | 195% | 63% | 194% | 437% | 373% | 64% | 37% | 55% | 55% | 229% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 62.73 | 67.16 | 54.13 | 49.81 | 35.45 | 35.32 | 33.23 | 22.23 | 26.75 | 26.42 | 25.86 | 28.24 |
| Inventory Days | 210.09 | 206.51 | 152.04 | 146.77 | 191.00 | 208.65 | 117.86 | 115.06 | 167.70 | 137.28 | 160.90 | 121.05 |
| Days Payable | 103.39 | 100.86 | 58.22 | 38.75 | 60.93 | 83.69 | 70.57 | 69.63 | 98.30 | 46.96 | 51.05 | 51.68 |
| Cash Conversion Cycle | 169.43 | 172.82 | 147.94 | 157.84 | 165.52 | 160.28 | 80.52 | 67.67 | 96.15 | 116.75 | 135.70 | 97.61 |
| Working Capital Days | 68.47 | 104.73 | 60.69 | 30.16 | 40.10 | 72.06 | 39.51 | 42.41 | 52.33 | 56.75 | 62.80 | 41.96 |
| ROCE % | 6.80% | 7.75% | 4.26% | 5.14% | 5.58% | 4.13% | 5.59% | 6.94% | 6.08% | 5.36% | 5.47% | 6.43% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 42.91% | 42.91% | 42.91% | 42.91% | 42.91% | 42.91% | 42.91% | 42.91% | 42.91% | 37.79% | 37.79% | 37.79% |
| DIIs | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public | 57.10% | 57.10% | 57.09% | 57.09% | 57.09% | 57.09% | 57.09% | 57.08% | 57.09% | 62.19% | 62.20% | 62.20% |
| No. of Shareholders | 10,103 | 10,021 | 10,001 | 10,012 | 10,246 | 10,333 | 10,287 | 10,226 | 10,284 | 10,284 | 10,298 | 10,268 |
Fundamentals
Market Cap₹ 36.2 Cr.
Current Price₹ 37.4
Stock P/E20.4
Book Value₹ 45.2
ROCE6.43 %
ROE4.13 %
Dividend Yield2.67 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)4%
Compounded Profit Growth (TTM)10%
Standalone figures.
Valuation
Market capRs 35 Cr
Enterprise valueRs 29 Cr
P/E (TTM)19.94x
Price to book0.81x
Price to sales0.51x
EV / EBITDA8.27x
EV / EBIT10.23x
EV / sales0.41x
Price to cash flow5.77x
Earnings yield5.02%
P/E, 3-year average28.39x
P/B, 3-year average1.06x
P/E, 5-year average31.47x
P/B, 5-year average1.23x
Profitability
Operating margin (excl. other income)4.29%
Operating margin (incl. other income)4.92%
EBITDA margin4.96%
Pre-tax margin3.84%
Net profit margin2.54%
Net margin, latest quarter1.40%
ROE4.13%
ROCE6.43%
ROA3.17%
ROE, 3-year average3.85%
ROCE, 3-year average5.75%
ROA, 3-year average2.93%
ROE, 5-year average4.02%
ROCE, 5-year average6.06%
ROA, 5-year average3.00%
ROIC (approx.)5.02%
Tax rate33.58%
Other income / net worth1.01%
Growth
Sales growth (latest year)4.08%
Profit growth (latest year)14.19%
Sales CAGR, 3 years2.28%
Sales CAGR, 5 years3.54%
Profit CAGR, 3 years5.21%
Profit CAGR, 5 years10.18%
Sales growth QoQ-2.73%
Profit growth QoQ475.00%
Sales growth YoY (latest quarter)-1.86%
Profit growth YoY (latest quarter)4.55%
Per share
EPS (TTM)Rs 1.83
EPS (latest year)Rs 1.83
EPS (latest quarter)Rs 0.24
EPS, 3-year averageRs 1.65
EPS, 5-year averageRs 1.67
Book value per shareRs 45.20
Sales per shareRs 72.06
Cash flow per shareRs 6.33
Free cash flow per shareRs 5.59
Dividend per share, 3-year averageRs 0.80
Dividend per share, 5-year averageRs 0.78
Dividends
Dividend payout, 3-year average51.21%
Dividend payout, 5-year average47.98%
Efficiency
Asset turnover1.25x
Fixed asset turnover3.86x
Inventory turnover3.64x
Inventory days100 days
Debtor days28 days
Debtors turnover12.93x
Creditor days52 days
Cash conversion cycle98 days
Working capital days42 days
Leverage
Total debtRs 0 Cr
Cash and bankRs 7 Cr
Net debtRs -7 Cr
Debt to equity0.00x
Net debt / EBITDA-1.96x
Interest coverage23.25x
Owners' fund to total sources78.16%
Debt to assets0.20%
Cash flow
Cash from Operating Activity (latest year)Rs 6 Cr
Cash from Investing Activity (latest year)Rs -1 Cr
Cash from Financing Activity (latest year)Rs -1 Cr
Net Cash Flow (latest year)Rs 5 Cr
Free cash flow (latest year)Rs 5 Cr
FCFE (approx.: FCF + change in debt)Rs 5 Cr
Cash from ops / profit, 5 years1.14x
Sales to cash flow11.43x
Statement figures
Net sales (TTM)Rs 70 Cr
Net sales (latest year)Rs 70 Cr
Sales (latest quarter)Rs 16 Cr
Operating profit excl. other income (latest year)Rs 3 Cr
Operating profit (latest quarter)Rs 1 Cr
Other income (TTM)Rs 0 Cr
EBITDA (TTM)Rs 3 Cr
PBDT (TTM)Rs 3 Cr
Profit before tax (TTM)Rs 3 Cr
Tax (latest year)Rs 1 Cr
Net profit (TTM)Rs 2 Cr
Net profit (latest year)Rs 2 Cr
Net profit (latest quarter)Rs 0 Cr
Depreciation (TTM)Rs 1 Cr
Depreciation (latest quarter)Rs 0 Cr
Interest (TTM)Rs 0 Cr
Cost of goods sold (latest year)Rs 38 Cr
Total expenditure (latest year)Rs 67 Cr
Total income (latest year)Rs 70 Cr
Share capitalRs 10 Cr
ReservesRs 34 Cr
Shareholders' fundsRs 44 Cr
Total assetsRs 56 Cr
Net blockRs 18 Cr
Capital work in progressRs 0 Cr
InvestmentsRs 12 Cr
ReceivablesRs 5 Cr
InventoryRs 10 Cr
Other liabilitiesRs 12 Cr
Shares outstanding (crore)0.97
Ownership
Promoter holding37.79% (-5.12 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 19.9 is at the 5th percentile of its own 8.4-year range
(median 37.6, low 14.4, high 67.4).
P/B 0.81 is at the 22th percentile (median 1.10).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | 524703 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -1.3% | -2.8% | +1.5 pts |
| 1 month | -1.5% | -6.8% | +5.3 pts |
| 3 months | -10.9% | -7.6% | -3.3 pts |
| 3 years | -50.7% | +14.2% | -64.9 pts |
| 5 years | -25.8% | +27.9% | -53.7 pts |
Red flags
F-score 7 of 8No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹16 Cr -1.9% vs Jun 2025.
Net profit ₹0 Cr +4.5%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Sandu Pharmaceuticals Ltd?
Sandu Pharmaceuticals Ltd (524703) has a market capitalisation of Rs 36.2 Cr. at the 2026-10-01 close.
What is the P/E ratio of Sandu Pharmaceuticals Ltd?
Sandu Pharmaceuticals Ltd trades at a P/E of 20.4 on trailing twelve-month profit, at the 2026-10-01 close.
What were Sandu Pharmaceuticals Ltd's latest quarterly results?
In the Jun 2026 quarter, Sandu Pharmaceuticals Ltd sales was Rs 16 Cr (-1.9% vs Jun 2025) and net profit was Rs 0 Cr.